The DOI matches its Crossref record; 244 of the 244 references it cites were found in a registry or an index.
Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics
Open accessAbstract
We recently reviewed the status of peptide and nonpeptide agonists and antagonists for the V 1a , V 1b and V 2 receptors for arginine vasopressin (AVP) and the oxytocin receptor for oxytocin (OT). In the present review, we update the status of peptides and nonpeptides as: (i) research tools and (ii) therapeutic agents. We also present our recent findings on the design of fluorescent ligands for V 1b receptor localisation and for OT receptor dimerisation. We note the exciting discoveries regarding two novel naturally occurring analogues of OT. Recent reports of a selective VP V 1a agonist and a selective OT agonist point to the continued therapeutic potential of peptides in this field. To date, only two nonpeptides, the V 2 /V 1a antagonist, conivaptan and the V 2 antagonist tolvaptan have received Food and Drug Administration approval for clinical use. The development of nonpeptide AVP V 1a , V 1b and V 2 antagonists and OT agonists and antagonists has recently been abandoned by Merck, Sanofi and Pfizer. A promising OT antagonist, Retosiban, developed at Glaxo SmithKline is currently in a Phase II clinical trial for the prevention of premature labour. A number of the nonpeptide ligands that were not successful in clinical trials are proving to be valuable as research tools. Peptide agonists and antagonists continue to be very widely used as research tools in this field. In this regard, we present receptor data on some of the most widely used peptide and nonpeptide ligands, as a guide for their use, especially with regard to receptor selectivity and species differences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although these compounds bind selectively to their respective receptors in rodents, they have now been shown to exhibit relatively high affinities for both OXTR and AVPR1a in primates (27,28).”
From Comparative Perspectives on Oxytocin and Vasopressin Receptor Research in Rodents and Primates: Translational Implications (2016) · cites this paper as [28]
In the citing paper
“Simply comparing the binding characteristics of the most common ligands for the human and rat OT and AVP receptors reveals considerable variation in pharmacological properties across species (28).”
From Comparative Perspectives on Oxytocin and Vasopressin Receptor Research in Rodents and Primates: Translational Implications (2016) · cites this paper as [28]
In the citing paper
“For example, studies employing recombinant expression systems to examine selectivity of human, rat, and mouse OT and AVP receptors have shown that only the human OTR is selective for OT using a standard criterion [34; 35] (Table 1).”
From Cross-talk among oxytocin and arginine-vasopressin receptors: Relevance for basic and clinical studies of the brain and periphery (2018) · cites this paper as [35]
In the citing paper
“The limited information on the distributions of OTR and V1aR in primate neural tissue is due in part to the lower selectivity for radioligands targeting OTR (125I-OVTA) and V1aR (125I-LVA) autoradiography, relative to high selectivity of radioligands for these receptors in rodents, as well as the promiscuous binding profile of both radioligands for OTR and V1aR (Freeman et al., 2014a, 2014b; Man”
From Neuropeptide diversity and the regulation of social behavior in New World primates (2016) · cites this paper as Manning et al., 2012
In the citing paper
“There was also no difference in AVP levels, suggesting no peripheral cross-reactivity, which is more likely to occur with higher levels of oxytocin exposure.71”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calcium's Role in Mechanotransduction during Muscle Development
Damm, T. B., & Egli, M. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000356667 · Cited by 14,552
Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide
Merrifield, R. B. (1963) · Journal of the American Chemical Society · doi:10.1021/ja00897a025 · Cited by 7,825
Inositol Trisphosphate, a Novel Second Messenger in Cellular Signal Transduction
Berridge, M. J., & Irvine, R. F. (1984) · Nature · doi:10.1038/312315a0 · Cited by 6,086
A highly sensitive adenylate cyclase assay
Salomon, Y., Londos, C., & Rodbell, M. (1974) · Analytical Biochemistry · doi:10.1016/0003-2697(74)90222-x · Cited by 4,135
The oxytocin receptor system: structure, function, and regulation
Gimpl, G., & Fahrenholz, F. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.629 · Cited by 3,089
Stewart, J. M. (1976) · Journal of Macromolecular Science Part A - Chemistry · doi:10.1080/00222337608068099 · Cited by 1,770
Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine
Meyer-Lindenberg, A., Domes, G., Kirsch, P., & Heinrichs, M. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3044 · Cited by 1,688
Oxytocin Modulates Neural Circuitry for Social Cognition and Fear in Humans
Kirsch, P., Esslinger, C., Chen, Q., Mier, D., Lis, S., Siddhanti, S., Gruppe, H., Mattay, V. S., Gallhofer, B., & Meyer-Lindenberg, A. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3984-05.2005 · Cited by 1,639
Synthetic therapeutic peptides: science and market
Vlieghe, P., Lisowski, V., Martínez, J., & Khrestchatisky, M. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.009 · Cited by 1,523
Tolvaptan, a Selective Oral Vasopressin V 2 -Receptor Antagonist, for Hyponatremia
Schrier, R. W., Gross, P., Gheorghiade, M., Berl, T., Verbalis, J. G., Czerwiec, F. S., & Orlandi, C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065181 · Cited by 1,215
Flagged first, then by citations
Research works printed but not linked: 13
- Manning M, 1981, The Pituitary, 265
- Manning M, 1985, Development of Selective Agonists and Antagonists of Vasopressin and Oxytocin, 131
- Manning M, 1991, Vasopressin, 297
- Manning M, 2005, Peptides 2004, 101
- Lebl M, 1988, Handbook of Neurohypophyseal Hormone Analogs, 17
- Jard S, 1998, Adv Exp Med Biol, 1
- 10.1210/en.137.9.3906 · DOI
- Wisniewski K, 2010, Peptides 2010, 306
- Manning M, 2010, Peptides 2010, 366
- Guillon G, 2007, Peptides 2006, 742
- 10.1021/jm010526 · DOI
- Mimoun MB, 2001, Peptides 2000, 589
- Reichert J, 2010, Development Trends for Peptide Therapeutics
Cited by
Sorted by citations
Items 401–429 of 429
Hu, S., Wang, Y., Han, X., Dai, M., Zhang, Y., Ma, Y., Weng, S., & Xiao, L. (2022) · Figshare · doi:10.6084/m9.figshare.21175657
Hu, S., Wang, Y., Han, X., Dai, M., Zhang, Y., Ma, Y., Weng, S., & Xiao, L. (2022) · Figshare · doi:10.6084/m9.figshare.21175651
Pair bonding, mating systems, and hormones in vertebrates
Laser, R. S., & Ophir, A. G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29068-8.00158-6
Sartorius, A. M., van der Meer, D., Shadrin, A. A., Rokicki, J., Campbell, M. L., Winterton, A., Andreassen, O. A., Schwarz, E., Nærland, T., Westlye, L. T., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03508-4
Caractérisation d’outils pharmacologiques pour l’étude des récepteurs centraux de la vasopressine
Marir, R. (2013) · theses.fr (ABES) · doi:10.70675/547ee25cz6fbfz417azabc9z92de6a7a2fcc
Conséquences pharmacologiques et fonctionnelles de l'hétérodimérisation des récepteurs V1B et CRF1
Mion, J. (2013) · theses.fr (ABES) · doi:10.70675/91d47531z8447z44d1z9f7ezf39a8e060318
Circuits neuronaux sous-tendant la régulation émotionnelle par le système ocytocinergique
Goyon, S. (2018) · theses.fr (ABES) · doi:10.70675/c8c9bec0z7b79z4826z862az93b128e1ada6
Prato, L. C. D. (2019) · theses.fr (ABES) · doi:10.70675/dd91f911z64bbz44d4z84b6ze6b58dbec750
Structure-based design of antiviral drugs against respiratory viruses using in silico approaches
Ruano, L. C. (2024) · theses.fr (ABES) · doi:10.70675/434de13dz7ff8z46beza24ezfaf0740f7dea
Fouillen, A., Couvineau, P., Mouillac, B., & Bous, J. (2026) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2026.112835
Self-citationNonapeptide modulation of looming-induced responses in male Betta splendens
Fusani, B., Cardoso, S. D., Ramos, A., & Gonçalves, D. (2026) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2026.114965
Lu, X., Wang, Q., Bai, H., Li, Z., Liu, H., Bian, C., Han, X., & Wang, P. (2026) · RSC Advances · doi:10.1039/d6ra03337g
Innate anxiety in rats determines vulnerability to social fear conditioning and social fear memory
Masís-Calvo, M., Rappeneau, V., & Neumann, I. D. (2026) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2026.107981
Hypothalamic supraoptic and paraventricular nuclei
Krabichler, Q., & Grinevich, V. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-24078-2.00012-7
Inada, K. (2026) · Neuroscience Research · doi:10.1016/j.neures.2026.105109
Hypertension fuels osteoarthritis through neuroendocrine signaling
Kim, S.-J., Kim, H., Chung, K., Lee, G., Park, K. H., Kim, Y.-G., Kim, M., Choi, W.-Y., Joo, S.-C., Kee, H. J., et al. (2026) · Science · doi:10.1126/science.aed8207 · Cited by 1
BindingDB Entry 50000104: Potent and selective oxytocin receptor agonists without disulfide bridges.
BindingDB (2019) · UC San Diego · doi:10.7270/q2br8v9q
BindingDB Entry 50020487: Photoswitchable Probes of Oxytocin and Vasopressin.
BindingDB (2024) · UC San Diego · doi:10.7270/q27h1q2x
BindingDB Entry 50022746: Macrocyclic-based strategy in drug design: From lab to the clinic.
BindingDB (2026) · UC San Diego · doi:10.7270/q2bp07n1
BindingDB Entry 50009062: Discovery of Potent, Selective, and Short-Acting Peptidic V
BindingDB (2021) · UC San Diego · doi:10.7270/q2pg1w51
BindingDB Entry 50045090: New, potent, and selective peptidic oxytocin receptor agonists.
BindingDB (2016) · UC San Diego · doi:10.7270/q2wd426v
Metadata
- Authors
- Manning, M., Misicka, A., Olma, A., Bankowski, K., Stoev, S., Chini, B., Durroux, T., Mouillac, B., Corbani, M., & Guillon, G.
- Affiliations
- University of Toledo (US)
- University of Warsaw (PL)
- Lodz University of Technology (PL)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Manning, M.
- Venue
- Journal of Neuroendocrinology
- Publisher
- Wiley
- Published
- 2012-03-26
- Volume
- 24
- Issue
- 4
- Pages
- 609-628
- ISSN
- 0953-8194 (ISSN-L)
- 1365-2826
- PMC
- PMC3490377
- OpenAlex
- W1803779312
- Cited by
- 423
- References
- 244
- Citations by year
- 2026: 14 · 2025: 20 · 2024: 22 · 2023: 25 · 2022: 32 · 2021: 36 · 2020: 31 · 2019: 40 · 2018: 34 · 2017: 35 · 2016: 28 · 2015: 29 · 2014: 38 · 2013: 30 · 2012: 8
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neuroendocrinology (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Institut National de la Santé et de la Recherche Médicale
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Centre National de la Recherche Scientifique
- National Institute of General Medical Sciences (GM25280, R01GM025280)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Neuroendocrine regulation and behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- oxytocin, vasopressin, vasopressin receptor, oxytocin receptor, V1a receptor, V1b receptor, V2 receptor, peptide agonists, peptide antagonists, conivaptan, tolvaptan, fluorescent ligands, receptor localization, receptor dimerization, oxytocin analogues, receptor selectivity, species differences
- MeSH terms
- Animals, Arginine Vasopressin, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Oxytocin, Structure-Activity Relationship, Receptors, Vasopressin, Receptors, Oxytocin, Antidiuretic Hormone Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
